-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, an authoritative journal in the field of neurology published a research article in Neurology.
Researchers aim to use a retrospective matched cohort design to test the following hypothesis: that is , the overall and cancer of multiple sclerosis (MS) patients after the diagnosis of colorectal cancer The specific survival rate is lower than that of patients without MS
.
The researchers used population-based administrative data from Manitoba and Ontario to identify MS patients through validated case definitions, and contacted these cohorts with cancer registries to identify patients with colorectal cancer
.
Researchers matched non-MS patients 4:1 based on the birth year, gender, cancer diagnosis year, and region of colorectal cancer patients , and used Cox proportional hazard regression to compare and adjust cancer diagnosis age, cancer diagnosis year, income, region, and Elixhauser All-cause survival rates between cohorts of comorbidity scores
The researchers included 338 MS cases and 1352 colorectal cancer controls
.
The average (SD) age at the time of cancer diagnosis was 64.
7 (11.
1) years
In the early stages after the diagnosis of colorectal cancer, the overall and cancer-specific survival rates of MS patients are low
Original source:
Susanna C.
Larsson.
et al.
Colorectal Cancer Survival in Multiple Sclerosis: A Matched Cohort Study .
Neurology.
2021.
Colorectal Cancer Survival in Multiple Sclerosis: A Matched Cohort Study Leave a message here
